What You Should Know
- The Consolidation: Samsung Medison is officially retiring the NeuroLogica and Boston Imaging brands. The U.S. medical imaging businesses are unifying under a single corporate identity: Samsung HME (Healthcare and Medical Equipment) America.
- The Unified Portfolio: This transition integrates Samsung’s U.S. ultrasound, digital radiography, and computed tomography (CT) operations under one structural roof, reflecting the massive scale of the global Samsung brand.
- The AI Push: The newly unified company is aggressively leaning into artificial intelligence. This is highlighted by the recent rollout of their AI-powered R20 and Z20 ultrasound systems, as well as their strategic acquisition of Sonio, a French AI startup specializing in early-stage fetal abnormality detection.
- The Manufacturing Hub: Despite the rebranding, Samsung HME America will remain the global headquarters and primary manufacturing center for Samsung’s CT business, with a heavy R&D focus on next-generation photon-counting detector technology.
- The Strategic Goal: According to Chief Commercial Officer Tracy Bury, the unification is designed to streamline the customer experience, allowing healthcare providers to collaborate with a single, consistent vendor entity across multiple imaging modalities.
Why Samsung Just Consolidated Its U.S. Medical Imaging Empire
Samsung Medison announced that it is officially retiring the NeuroLogica and Boston Imaging brand names in the United States. Moving forward, the company’s entire U.S. ultrasound, digital radiography, and computed tomography (CT) operations will operate under a single banner: Samsung HME (Healthcare and Medical Equipment) America.
“This milestone represents more than a name change,” noted Kyu Tae Yoo, CEO of Samsung Medison. “It reinforces Samsung’s long-term commitment to healthcare providers nationwide and reflects the growth and maturity of our U.S. medical imaging organization.”
While the name change simplifies the procurement process for health systems, it also serves as a critical runway for Samsung’s aggressive push into artificial intelligence.
Over the past year, Samsung has been quietly building a formidable AI imaging ecosystem. They recently launched the R20 and Z20 ultrasound systems, which heavily leverage AI-powered tools to automate workflows and support clinical decision-making. Furthermore, their acquisition of the French startup Sonio brings highly specialized, AI-driven prenatal abnormality detection into their native tech stack.
Under Samsung HME America, the company can now sell this AI ecosystem cohesively across all imaging modalities, rather than pitching fragmented software solutions from isolated business units.
